U.S. Pharmaceuticals & Biotech Healthy high growth potential

Madrigal Pharmaceuticals

Market Cap: US$12.6b

A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.

Corcept Therapeutics

Market Cap: US$10.1b

A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

Axsome Therapeutics

Market Cap: US$12.9b

A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.

Syndax Pharmaceuticals

Market Cap: US$2.1b

A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.

Marker Therapeutics

Market Cap: US$28.0m

A clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.

Ardelyx

Market Cap: US$1.3b

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.

Krystal Biotech

Market Cap: US$10.9b

A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.

Aldeyra Therapeutics

Market Cap: US$134.5m

A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.

RenovoRx

Market Cap: US$41.8m

A clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.

Achieve Life Sciences

Market Cap: US$669.3m

A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.

Lineage Cell Therapeutics

Market Cap: US$329.1m

A clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally.

Forum Markets

Market Cap: US$75.3m

A financial technology company, develops a blockchain-based platform focused on the acquisition, structuring, and tokenization of real-world assets worldwide.

Tenaya Therapeutics

Market Cap: US$199.6m

A clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.

Zevra Therapeutics

Market Cap: US$853.6m

A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.

Alnylam Pharmaceuticals

Market Cap: US$42.9b

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

Intellia Therapeutics

Market Cap: US$2.4b

Operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.

Capricor Therapeutics

Market Cap: US$1.3b

A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.

Hyperion DeFi

Market Cap: US$43.4m

A DeFi company, engages in building on Hyperliquid.

Viridian Therapeutics

Market Cap: US$2.3b

Engages in discovering, developing, and commercializing treatments for serious and rare diseases.

Codexis

Market Cap: US$236.3m

Provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.

Citius Oncology

Market Cap: US$66.0m

Focuses on the development and commercialization of targeted oncology therapies.

CG Oncology

Market Cap: US$6.1b

A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.

Eton Pharmaceuticals

Market Cap: US$1.0b

A pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.

BioStem Technologies

Market Cap: US$58.2m

Engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.

Longeveron

Market Cap: US$20.0m

A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.

Arcutis Biotherapeutics

Market Cap: US$3.5b

A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.

Humacyte

Market Cap: US$207.9m

Engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.

Kiniksa Pharmaceuticals International

Market Cap: US$5.2b

A biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.

AC Immune

Market Cap: US$246.5m

A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.

Larimar Therapeutics

Market Cap: US$355.9m

A clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.

Belite Bio

Market Cap: US$5.8b

A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States.

NewAmsterdam Pharma

Market Cap: US$4.3b

A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.

MediciNova

Market Cap: US$70.9m

A biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.

Insmed

Market Cap: US$24.5b

Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.

SIGA Technologies

Market Cap: US$263.2m

A commercial-stage pharmaceutical company, focuses on the health security market in the United States.

Vera Therapeutics

Market Cap: US$3.0b

A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.